Impact of Transition to Insulin U-500 during Pregnancy on Continuous Glucose Monitoring–Derived Glycemic Metrics among Women with Type 2 Diabetes
American Journal of Perinatology · 21.10.2026
DOI: 10.1055/a-2979-5956 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, online erschienen am 21.10.2026. Verfasst von Elizabeth O Buschur und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Ohio State University, Department of Internal Medicine, Ohio, United States, Columbus. Die Arbeit nennt 13 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Insulin U-500 is a highly concentrated regular insulin that is five times stronger than standard U-100 and is used to treat severe insulin resistance. Glycemic data from continuous glucose monitoring (CGM) in relation to initiation of U-500 insulin in pregnancy with type 2 diabetes are limited. We examined CGM-derived glycemic measures before and after insulin U-500 transition during pregnancy among women with type 2 diabetes. We conducted a case-crossover study evaluating glycemic measures before and after transition to insulin U-500 during pregnancy among women with type 2 diabetes. The case period was from prenatal care to insulin U-500 transition, and the control period was after insulin U-500 transition to delivery. Outcomes included CGM metrics (time in range [TIR; 65–140 mg/dL], time above range [TAR], and time below range), mean glucose and standard deviation, estimated A1c per glucose management indicator, coefficient of variation, and number of hypoglycemic episodes and were compared pre versus post insulin U-500 transition. Adjusted linear mixed models were used. Among 21 women with type 2 diabetes, the median gestational age at prenatal care initiation was 11.1 weeks, at insulin U-500 transition was 25.4 weeks, and at delivery was 37.1 weeks. The insulin U-500 dose at initiation was 300 units/day and at delivery was 422.5 units/day. The TIR was higher, and TAR and mean glucose were lower post versus pre insulin U-500 transition (p < 0.05). In this cohort of pregnant women with type 2 diabetes, transition to insulin U-500 was associated with a modest improvement in some CGM-derived glycemic measures.
Autor:innen und Institutionen
- The Ohio State University, Department of Internal Medicine, Ohio, United States, Columbus.
- The Ohio State University, Department of Obstetrics and Gynecology, Ohio, United States, Columbus.
- Brown University, Department of Obstetrics and Gynecology, Rhode Island, United States, Providence.
ORCID-Profile: Christine P Field, Kartik K Venkatesh
Zitieren
APA
Buschur, E. O., Scheiber, A., Wu, J., Brewton, A., Gabbe, S. G., Vickers, S., Landon, M. B., Lynch, C., Grobman, W. A., Field, C. P., & Venkatesh, K. K. (2026). Impact of Transition to Insulin U-500 during Pregnancy on Continuous Glucose Monitoring–Derived Glycemic Metrics among Women with Type 2 Diabetes. American Journal of Perinatology. https://doi.org/10.1055/a-2979-5956
Vancouver
Buschur EO, Scheiber A, Wu J, Brewton A, Gabbe SG, Vickers S, et al. Impact of Transition to Insulin U-500 during Pregnancy on Continuous Glucose Monitoring–Derived Glycemic Metrics among Women with Type 2 Diabetes. American Journal of Perinatology. 2026. doi:10.1055/a-2979-5956
BibTeX
@article{Buschur2026,
author = {Buschur, Elizabeth O and Scheiber, Alexandra and Wu, Jiqiang and Brewton, Annabeth and Gabbe, Steven G and Vickers, Shaylyn and Landon, Mark B and Lynch, Courtney and Grobman, William A and Field, Christine P and Venkatesh, Kartik K},
title = {Impact of Transition to Insulin U-500 during Pregnancy on Continuous Glucose Monitoring–Derived Glycemic Metrics among Women with Type 2 Diabetes},
journal = {American Journal of Perinatology},
year = {2026},
doi = {10.1055/a-2979-5956}
}
EUVIMED